Supreme Court wants cap on trade margin for all essential medicines and medical products
Worth reading — New development — a live issue with two sides, good for Mains, no past question yet.
2-minute summary
The Supreme Court of India questioned the Central government regarding why the proposed 30% trade-margin cap on patented and non-patented cancer medicines cannot be extended to all essential medicines and medical products. A Bench of Justices Vikram Nath and Sandeep Mehta highlighted stark disparities between the price to retailer (PTR) and the maximum retail price (MRP), noting that some mark-ups soar up to 1,000% and describing exorbitant mark-ups as 'broad daylight dacoity'. While the Centre defended leaving room for market forces and cited the risk of retailers abandoning low-margin products, the apex court emphasized that ensuring price-controlled medicines reach patients is the government's responsibility and gave the Centre until October 27 to work out modalities for wider price capping.
Why it's in the news
The Supreme Court pulled up the Centre over exorbitant mark-ups in healthcare products and directed it to explain why a trade-margin cap should not apply to all essential medicines beyond cancer drugs.
Facts to remember
- The Central government proposed a 30% trade-margin cap on patented and non-patented cancer medicines.
- The National Pharmaceutical Pricing Authority (NPPA) examines expert committee recommendations to issue price notifications under the Drugs (Prices Control) Order.
- The Drugs (Prices Control) Order (DPCO), 2013 prescribes a 16% retailer margin for scheduled price-controlled medicines.
- The Supreme Court Bench hearing the matter comprised Justices Vikram Nath and Sandeep Mehta.
- The Centre submitted a 551-page affidavit defending its pricing policy and market-play considerations.
Background and context
The regulation of pharmaceutical prices in India is primarily governed by the Drugs (Prices Control) Order (DPCO), issued under Section 3 of the Essential Commodities Act, 1955. The National Pharmaceutical Pricing Authority (NPPA), established in 1997 as an independent body of the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers), is tasked with fixing and revising prices of scheduled formulations and enforcing price caps. Historically, price control focused on a fixed list of essential medicines (National List of Essential Medicines - NLEM). However, the massive gap between the price to retailer (PTR) and the maximum retail price (MRP) charged by stockists, distributors, and private hospitals on unregulated or non-scheduled products (such as medical devices, consumables, and cancer drugs) has repeatedly drawn judicial scrutiny. Courts and consumer bodies have argued that exorbitant trade mark-ups defeat the objective of affordable healthcare, while industry representatives contend that a blanket cap could hurt retail viability and supply chains.
Constitutional provisions
- Article 21 — Right to health and access to affordable medical care as an intrinsic component of the Right to Life.
- Article 142 — Supreme Court invoking its plenary powers to do complete justice in matters concerning public welfare and healthcare pricing.
Committees and reports
- Expert Committee headed by the Director General of Health Services — Tasked with identifying cancer and other drugs to be brought under the proposed trade-margin rationalisation framework.
Government schemes
- National Pharmaceuticals Pricing Policy (NPPP) — Governs the pricing framework and rationale for essential medicines and price ceilings in India.
Mains practice: Examine the role of judicial intervention in shaping public healthcare and pharmaceutical pricing policy in India. What are the economic trade-offs of imposing blanket trade-margin caps on medical products?
Introduction
Access to affordable healthcare is an essential adjunct to the Right to Life under Article 21 of the Constitution. Recent observations by the Supreme Court questioning the exemption of non-cancer essential medicines from trade-margin caps highlight the growing judicial push to rein in exorbitant out-of-pocket medical expenditures.
Constitutional and Regulatory Framework
• The primary legislative anchor for drug price control in India is the Essential Commodities Act, 1955, under which the Drugs (Prices Control) Order (DPCO), 2013 is promulgated.
• The National Pharmaceutical Pricing Authority (NPPA), functioning under the Ministry of Chemicals and Fertilizers, regulates scheduled formulation prices.
• Judicial Activism: Courts have stepped in when statutory mechanisms failed to curb extreme mark-ups—such as medical devices and consumables sold at multiples of their procurement cost—framing such practices as an infringement of consumer rights.
Economic Trade-offs of Trade-Margin Capping
• Affordability vs. Availability: While capping margins protects consumers from predatory pricing, pharmaceutical associations and government affidavits warn that overly rigid caps on low-value items may render them commercially unviable for retailers, leading to supply shortages in rural areas.
• Innovation and R&D: Price controls can diminish profit margins required by domestic pharmaceutical firms to fund research and development for patented formulations and advanced therapies.
• Distribution Efficiency: A balanced pricing model is necessary to preserve reasonable incentives for stockists and private hospitals while preventing arbitrary mark-ups.
Way Forward
• Transparent Supply Chain: Implement mandatory end-to-end digital tracking of medical devices and consumables from manufacturer to patient to curb intermediate profiteering.
• Differentiated Price Caps: Instead of a rigid blanket cap, adopt a graded trade-margin rationalisation based on product categories, logistics costs, and essentiality as recommended by expert bodies.
• Strengthening Public Healthcare: Expand public procurement and distribution of essential drugs and devices to reduce reliance on private hospital supply chains.
Conclusion
Striking a fine balance between consumer protection and commercial viability is vital. Ensuring that price-regulated medicines actually reach vulnerable patients requires robust enforcement mechanisms by regulatory bodies in tandem with judicial oversight, fulfilling the mandate of inclusive welfare under the Directive Principles of State Policy.
Prelims practice questions
Q1. Consider the following statements regarding drug price regulation in India: 1. The Drugs (Prices Control) Order (DPCO) is promulgated under the Essential Commodities Act, 1955. 2. The National Pharmaceutical Pricing Authority (NPPA) functions under the administrative control of the Ministry of Chemicals and Fertilizers. 3. The Supreme Court recently questioned why the proposed trade-margin cap should not be extended to all essential medicines and medical products. How many of the above statements are correct? (A) Only one (B) Only two (C) All three (D) None
- Only one
- Only two
- All three
- None
Answer: C. All three statements are correct. The DPCO is issued under the Essential Commodities Act, the NPPA is under the Ministry of Chemicals and Fertilizers, and the Supreme Court recently directed the Centre to justify limiting trade-margin caps only to cancer drugs.
Q2. Consider the following statements regarding the regulation of pharmaceutical pricing in India: 1. The National Pharmaceutical Pricing Authority is a statutory body established directly by an Act of Parliament in 2013. 2. Scheduled formulations under the DPCO are subject to price ceilings fixed by the government. Which of the statements given above is/are correct? (A) 1 only (B) 2 only (C) Both 1 and 2 (D) Neither 1 nor 2
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: B. Statement 1 is incorrect because the NPPA was established as an attached office (executive body) of the Department of Pharmaceuticals in 1997, not by a direct Act of Parliament in 2013. Statement 2 is correct as scheduled formulations under DPCO have price ceilings fixed by the regulator.
Q3. What is the primary statutory instrument used by the Government of India to regulate and control the prices of essential drugs in the country?
- The Drugs (Prices Control) Order, 2013
- The Drugs and Cosmetics Act, 1940
- The Pharmacy Act, 1948
- The Consumer Protection Act, 2019
Answer: A. The Drugs (Prices Control) Order (DPCO), 2013, issued under the Essential Commodities Act, is the primary instrument through which the government fixes ceiling prices and regulates trade margins for essential medicines in India.
Revision flashcards
- Which ministry oversees the National Pharmaceutical Pricing Authority (NPPA) in India? Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals).
- Under which central legislation is the Drugs (Prices Control) Order (DPCO) promulgated? The Essential Commodities Act, 1955.
- In October 2026, what trade-margin cap did the Centre propose for cancer medicines before the Supreme Court? A 30% trade-margin cap on both patented and non-patented cancer medicines.
- As of October 2026, what standard retailer margin is prescribed under the Drugs (Prices Control) Order (DPCO), 2013 for scheduled medicines? A 16% retailer margin.
- Why has the Supreme Court urged the expansion of trade-margin caps beyond cancer drugs? To prevent exorbitant mark-ups (up to 1,000%) between the price to retailer and maximum retail price on essential medical products.